NCT00077883 - TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

TLK286, cisplatin

TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).

Trial Locations (3)

21201

Univ. of MD, Greenbaum Cancer Center, Baltimore

37203

The Sarah Cannon Cancer Center, Nashville

77030

Univ. of TX, MD Anderson Cancer Center, Houston